Enterprise value to EBITDA forward of Innoviva, Inc. – SWB:HVE
This article provides financial information for Innoviva, Inc. (SWB:HVE) focusing on its Enterprise Value to EBITDA forward. It is presented on the TradingView platform, which offers various financial tools and market data services.
Price to sales forward of Innoviva, Inc. – SWB:HVE
This page from TradingView provides a financial overview of Innoviva, Inc. (SWB:HVE) listed on the Stuttgart Stock Exchange, specifically focusing on its forward price-to-sales ratio. While the article highlights the financial metric, no specific values or analytical details are presented on this particular page. The rest of the content consists of navigation links and general platform information.
INVA - Innoviva Inc Latest SEC Filings
This article provides the latest SEC filings information for Innoviva Inc (INVA), alongside comprehensive financial data and performance metrics. It includes details on market capitalization, income, sales, dividend information, various financial ratios, share performance, and analyst recommendations. The data indicates Innoviva Inc's current financial health and market position.
Is Innoviva (INVA) Trading Index Membership for a Deeper Bet on Nortiva Bio’s LYNX Platform?
Innoviva (INVA) was recently delisted from several Russell growth indices, including the Russell 2000 and 3000 Growth benchmarks, coinciding with its strategic shift towards building Nortiva Bio and the LYNX long-acting oral drug delivery platform. This removal may impact liquidity and introduce short-term volatility, but doesn't alter core operations, pipeline, or buybacks. Investors now face weighing potential funding needs for Nortiva, reduced index presence, and forecast earnings pressure, although the company maintains a cash-generative royalty and anti-infectives business.
Is Innoviva (INVA) Trading Index Membership for a Deeper Bet on Nortiva Bio’s LYNX Platform?
Innoviva, Inc. (INVA) was recently removed from several Russell growth indices, including the Russell 2000 and 3000 Growth benchmarks, coinciding with its strategic shift to build Nortiva Bio around the LYNX drug delivery platform. This change may impact the company's trading liquidity and introduce short-term volatility, but its core operating drivers, pipeline progress, and buybacks remain unaffected. Investors should consider the potential funding needs for Nortiva and the effect of reduced index inclusion on sentiment, especially as earnings are forecast to soften, while evaluating the company's transition from a royalty business to a biopharmaceutical company focused on its new platform.
5 Cheap Small Cap Stocks to Buy Now
This article lists
Is Innoviva (INVA) Undervalued After Nortiva Bio Launch And XACDURO Deal?
Innoviva (INVA) has gained attention after launching Nortiva Bio and signing a distribution deal for XACDURO, leading to positive year-to-date and one-month share price returns. Despite a low P/E ratio of 3.4x compared to industry averages and analysts' price targets, the company faces declining earnings forecasts. However, a high Return on Equity and a Discounted Cash Flow (DCF) analysis suggest the stock is significantly undervalued, trading at a 59.1% discount to its estimated future cash flow value.
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell Small Cap Comp Growth Benchmark
Innoviva, Inc. (NasdaqGS: INVA) has been removed from the Russell Small Cap Comp Growth Benchmark. This news comes amidst recent corporate activities for Innoviva, including an acquisition of the LYNX platform and a licensing deal, as well as several earnings reports and board changes. The company, a diversified holding company with a focus on healthcare assets and royalties, was trading at $23.14 USD, down 1.82%.
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 3000 Growth Benchmark
Innoviva, Inc. (NasdaqGS: INVA) has been removed from the Russell 3000 Growth Benchmark. The pharmaceutical company, which specializes in respiratory assets and other healthcare products, recently announced an acquisition and a licensing deal, amidst reporting its Q1 revenue.
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership
Innoviva recently launched Nortiva Bio, a clinical-stage subsidiary focused on long-acting oral drug delivery, and partnered with Dr. Reddy's Laboratories for global distribution of XACDURO. These moves expand Innoviva's drug delivery technology exposure and global commercial footprint, but also introduce new clinical and execution risks alongside potential long-term upside. Investors are now weighing this richer R&D profile against the company's currently low earnings multiple and varying fair value estimates.
INVA Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Innoviva, Inc. (INVA) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, and financial data such as earnings, revenue, and EBITDA. The consensus among analysts suggests a strong buy signal for INVA, with future earnings and revenue expectations detailed.
INVA - Innoviva Inc Options
This article provides a detailed financial overview of Innoviva Inc (INVA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key statistics like EPS, insider and institutional ownership, profitability margins, and price performance over different periods.
Enterprise value to EBIT forward of Innoviva, Inc. – NASDAQ:INVA
This article provides financial information for Innoviva, Inc. (NASDAQ: INVA), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed at the time of publication and there were no trades. The article is a stub, likely from a financial data platform, with placeholders for actual financial data.
(INVA) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Innoviva Inc. (NASDAQ: INVA), highlighting strong sentiment across all time horizons and an exceptional 28.0:1 risk-reward setup. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The report was published by the Quantitative Research Desk and edited by Thomas H. Kee Jr.
Price to book forward of Innoviva, Inc. – NASDAQ:INVA
This article displays the "Price to book forward" financial metric for Innoviva, Inc. (NASDAQ: INVA) on TradingView. It indicates that the market was closed at the time of viewing, with no trades recorded for this specific metric.
Enterprise value to revenue forward of Innoviva, Inc. – GETTEX:HVE
This article provides financial information for Innoviva, Inc. (HVE) on the Gettex exchange, specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, displaying stock overview, financials, news, and community discussions. The content is primarily a navigation and data interface for financial analysis.
Innoviva, Inc. Actuals & Estimates (NASDAQ:INVA)
This article provides an overview of Innoviva, Inc. (NASDAQ:INVA) financial actuals and analyst estimates, covering income statements, balance sheets, and cash flow data. It offers details on the company's current stock price, historical performance, market capitalization, upcoming earnings reports, and analyst forecasts. The article also touches upon volatility, EBITDA, employee count, and guidance on how to buy INVA stocks and conduct research before investing.
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership
Innoviva (INVA) has introduced Nortiva Bio, a new subsidiary focused on long-acting oral drug delivery, and partnered with Dr. Reddy's Laboratories for global distribution of XACDURO. These strategic moves aim to diversify Innoviva's drug delivery technology and expand the reach of its anti-infective portfolio. While these initiatives introduce new clinical and execution risks, they also offer potential long-term upside in differentiated therapeutics, challenging investors to weigh against the company's current low earnings multiple.
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership
Innoviva (INVA) is expanding its drug delivery technology through a new clinical-stage subsidiary, Nortiva Bio, and has partnered with Dr. Reddy's Laboratories for global distribution of XACDURO. These initiatives aim to broaden Innoviva's market presence and technology portfolio, though they also introduce new clinical and execution risks alongside potential long-term benefits. While Innoviva's shares have risen, investor opinions on its fair value vary significantly, and the company's investment narrative now balances a cash-generative royalty base with these selective bets on differentiated therapeutics.
HVE Forecast — Price Target — Prediction for 2027
This article provides a forecast for Innoviva, Inc. (HVE) stock, including analyst price targets, future earnings, and revenue estimates. It highlights that the 4 analysts providing 1-year price forecasts have a range from 14.06 CHF to 35.93 CHF. The company's next earnings report is expected on July 29, 2026, with details on past performance and financial metrics like EBITDA also provided.
Price to sales forward of Innoviva, Inc. – GETTEX:HVE
This article provides financial information for Innoviva, Inc. (HVE) on the Gettex exchange, specifically focusing on its "Price to sales forward" metric. The content highlights a market overview, financial data, and other related information available on the TradingView platform for the company.
A2AC9U Forecast — Price Target — Prediction for 2027
This article provides a forecast for Innoviva, Inc. (A2AC9U) stock, including analyst price targets and future predictions for 2027. It details recent stock performance, historical highs and lows, financial metrics like earnings and revenue, and upcoming earnings dates. The content also addresses frequently asked questions about the company's stock, such as volatility, market capitalization, dividends, and technical analysis ratings.
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform
Innoviva, Inc. (NASDAQ:INVA) has launched Nortiva Bio, a biopharmaceutical company focused on developing long-acting oral therapies using its proprietary LYNX drug delivery platform. This platform aims to convert daily oral medicines into extended-release treatments with potential dosing intervals of up to one month, improving effectiveness, adherence, and patient experience. Additionally, Innoviva's subsidiary, Innoviva Specialty Therapeutics, has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in various international markets.
Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally
Innoviva Specialty Therapeutics (INVA) has partnered with Dr. Reddy’s Laboratories to expand access to its FDA-approved antibiotic, XACDURO, in South and Central America, the Caribbean, Russia, and the CIS region. This collaboration aims to combat high rates of carbapenem-resistant Acinetobacter infection in these areas. Dr. Reddy’s will handle development, regulatory approval, and commercialization, while Innoviva will receive upfront, milestone, and royalty payments.
Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally
Innoviva Specialty Therapeutics (INVA) has partnered with Dr. Reddy’s Laboratories to expand the international reach of its antibiotic, XACDURO. This collaboration will focus on South and Central America, the Caribbean, Russia, and the CIS region, where high rates of carbapenem-resistant Acinetobacter infections are a critical health challenge. Innoviva will receive an upfront payment, milestone payments, and royalties, while Dr. Reddy's will handle the development, regulatory approval, and commercialization in these territories.
Innoviva Inc (INVA) Institutional Confidence
Innoviva Inc (INVA) has a high institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion has increased by 1.43% quarter-over-quarter, now standing at 109.69%. James Simons is the largest institutional shareholder, holding 5.49% of outstanding shares.
Innoviva Price Target Maintained With a $42.00/Share by BTIG
BTIG has maintained its price target for Innoviva (INVA) at $42.00 per share. This indicates an analyst's continued confidence in the company's valuation at that level. The report suggests that BTIG sees Innoviva's stock reaching this price point.
Innoviva Is Maintained at Buy by BTIG
This article states that BTIG has maintained its "Buy" rating on Innoviva. No additional details are provided regarding the reasons for this rating or any financial analysis.
Will XACDURO Licensing Deal With Dr. Reddy’s Reshape Innoviva’s (INVA) Infectious Disease Strategy?
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., recently entered an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for XACDURO® across various international regions. This deal helps expand XACDURO®'s global reach and offers Innoviva potential revenue through upfront payments, milestones, and royalties. While not considered "transformational," it is seen as additive to Innoviva's investment narrative, leveraging partnerships for infectious disease commercialization outside the U.S.
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Nortiva Bio, a clinical-stage biopharmaceutical company and wholly-owned subsidiary of Innoviva, Inc., has officially launched to develop long-acting oral medicines. The company utilizes its proprietary LYNX™ drug delivery platform, which can transform daily pills into once-monthly therapies, aiming to improve adherence and patient outcomes across various therapeutic areas. Nortiva's initial focus includes a once-monthly oral contraceptive, supported by a Gates Foundation grant, and seeking partnerships to expand the application of its LYNX platform.
Innoviva Inc (INVA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Innoviva Inc (INVA), detailing its current earnings forecast score, average price target from analysts, and a breakdown of analyst ratings. It also includes expected revenue for the next quarter, past and future EPS performance, and a peer comparison within the Pharmaceuticals industry. The analysis is based on data provided by LSEG.
Innoviva spins out Nortiva Bio to make pills last up to a month
Innoviva, Inc. has officially launched Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. This platform aims to transform daily pills into single-dose therapies lasting up to a month, improving medication adherence and patient quality of life. Nortiva Bio's lead program is a once-monthly oral contraceptive, and the company is also seeking partnerships to apply the LYNX technology to other approved or development-stage small molecule therapies.
Innoviva Inc (INVA) Financial Health: Profitability & Balance Sheet Analysis
Innoviva Inc (INVA) demonstrates robust financial health, ranking 22nd out of 157 in the Pharmaceuticals industry with a financial score of 8.98. The company reported a 10.56% year-over-year increase in quarterly revenue to $97.99 million and a significant 500.56% year-over-year increase in net profit. Its operational efficiency and growth potential scores are both high at 10.00.
Innoviva Inc (INVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Innoviva Inc (INVA), focusing on business segments and regional contributions. It notes that relevant data for recent fiscal quarters (FY2025Q1, Q2, Q4) and FY2024 has not yet been disclosed by the company. However, it does show a United States regional revenue of $411.33 million with 0.00% proportion from the available data.
Innoviva Inc (INVA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Innoviva Inc's (INVA) historical dividend payouts and stock splits. It states that no dividend data is available for the past five years and no stock split data is found. The article also includes current stock performance metrics for INVA.
Innoviva Inc (INVA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Innoviva Inc (INVA), listing its major shareholders and their respective proportions. It also categorizes shareholders by type, such as investment advisors and hedge funds, and provides a historical overview of institutional shareholding and recent changes in holdings by key institutions. The data includes the number of institutions, shares held, and proportional changes over several quarters.
Innoviva Specialty Therapeutics inks distribution and licensing agreement with Dr. Reddy’s
Innoviva Specialty Therapeutics has partnered with Dr. Reddy’s Laboratories through an exclusive distribution and licensing agreement. This collaboration aims to develop and commercialize XACDURO® for the treatment of severe Acinetobacter baumannii-calcoaceticus complex infections in South and Central America, the Caribbean, Russia, and CIS countries. Dr. Reddy’s will manage development, regulatory, and commercialization, while Innoviva retains rights in other territories and will receive milestone payments and royalties.
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO
Innoviva Specialty Therapeutics has partnered with Dr. Reddy’s Laboratories for the distribution and licensing of XACDURO in select international markets including South and Central America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO, an antibiotic approved for serious Acinetobacter infections, in regions where carbapenem-resistant Acinetobacter rates are notably high. Dr. Reddy’s will manage development, regulatory, and commercialization activities in the licensed territories, while Innoviva Specialty Therapeutics will receive an upfront payment, milestone payments, and royalties.
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Innoviva Specialty Therapeutics has partnered with Dr. Reddy's Laboratories to distribute and commercialize the pneumonia drug XACDURO in Latin America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO, an antibiotic for hospital-acquired and ventilator-associated bacterial pneumonia caused by drug-resistant Acinetobacter, in regions with high rates of carbapenem-resistant infections. Innoviva will receive an upfront payment, milestone payments, and royalties, while Dr. Reddy's handles development, regulatory, and commercialization activities in the licensed territories.
Innoviva partners with Dr. Reddy's for XACDURO licensing
Innoviva Specialty Therapeutics has entered an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for its antibiotic XACDURO. Dr. Reddy's will handle the development and commercialization of the drug in South America, Central America, the Caribbean, and Russia, paying upfront fees, milestones, and royalties. Innoviva will retain commercial rights in other territories and focus on domestic execution.
Innoviva unit signs distribution deal with Dr. Reddy’s
Innoviva Specialty Therapeutics has signed an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd. for its antibiotic XACDURO in South and Central America, the Caribbean, Russia, and CIS countries. Innoviva Inc. (NASDAQ:INVA) is set to receive an upfront payment, milestone payments, and royalties, while retaining rights in other territories. The parent company, Innoviva, shows strong financial performance and is considered undervalued by InvestingPro analysis, despite recent board changes and an "Overweight" rating from Cantor Fitzgerald.
Responsive Playbooks and the INVA Inflection
This article analyzes Innoviva Inc. (NASDAQ: INVA) with a neutral near and mid-term outlook but a positive long-term bias. It highlights a strong risk-reward short setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strength, support, and resistance levels for the stock.
Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary
Innoviva (INVA) presented at the 47th Annual Goldman Sachs Global Healthcare Conference, highlighting its diversified business model comprising resilient royalty streams, a rapidly growing specialty therapeutics business (IST), and strategic healthcare assets. The company emphasized its strong royalty performance from asthma and COPD treatments, the significant annual growth of its IST division with products like XACDURO and GIAPREZA, and upcoming launches such as NUZOLVENCE. Innoviva aims to achieve $150 million in U.S. IST revenue by 2026 while continuing to expand its strategic investments in innovative healthcare companies.
Understanding the Setup: (INVA) and Scalable Risk
This article analyzes Innoviva Inc. (NASDAQ: INVA), highlighting divergent sentiment across different time horizons, suggesting choppy market conditions. It identifies a mid-channel oscillation pattern and outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles. The analysis also provides key support and resistance levels across near-term, mid-term, and long-term perspectives.
Understanding the Setup: (INVA) and Scalable Risk
This article analyzes Innoviva Inc. (NASDAQ: INVA), highlighting divergent market sentiment and a mid-channel oscillation pattern. It presents an exceptional 28.1:1 risk-reward short setup targeting an 8.7% downside and outlines three distinct AI-generated trading strategies for different risk profiles. The analysis includes multi-timeframe signal data, offering insights into near-term, mid-term, and long-term outlooks for INVA.
Innoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc., a diversified biopharmaceutical company, announced its participation in two upcoming investor conferences in June 2026. Management will attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th and the BTIG Infectious Disease Day on June 16th. The company invites interested parties to access a live webcast of the Goldman Sachs presentation and an archived replay on its investor relations website.
Innoviva Board Shift And New Treatment Launch Create Valuation Question
Innoviva (NasdaqGS:INVA) has appointed Josephine Linden to its Board following two director resignations related to Syndeio BioSciences, a company Innoviva supports. Concurrently, Innoviva is preparing to launch a newly approved gonorrhea treatment. These developments, set against an active share price near $21.42, prompt investors to consider the company's valuation, especially given its stock trades about 40% below analyst targets and 62.9% below estimated fair value.
Innoviva, Inc. to Present at Investor Conferences
Innoviva, Inc. announced its participation in upcoming investor conferences, where its management team will present business and strategic insights. These presentations offer a platform for Innoviva to discuss its financial performance, ongoing projects, and future outlook with both current and potential investors and analysts. The company aims to connect with the financial community and provide transparency on its operations.
Innoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc. (NASDAQ: INVA) announced its management will participate in two upcoming investor conferences in June: the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, and the BTIG Infectious Disease Day on June 16, 2026. A live webcast of the Goldman Sachs fireside chat will be available on the company's investor relations website, with an archived replay accessible afterward. Innoviva is a diversified biopharmaceutical company with a royalties portfolio, the Innoviva Specialty Therapeutics platform, and healthcare investment assets.
INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46
HC Wainwright & Co. has reiterated a "Buy" rating for Innoviva (INVA), maintaining a price target of $46.00, despite the stock being 5.7% overvalued according to GuruFocus's GF Value™. Innoviva, which operates in the biotechnology industry, has a strong GF Score™ of 90/100, indicating robust financial performance and profitability. However, the current valuation and a P/E ratio significantly lower than its 5-year median suggest a mixed picture for investors.
